Clinical trials: Plaque Psoriasis.
Moderate to Severe Plaque Psoriasis
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
Investigate the Safety, Tolerability, Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis
- Trial name
- NCT05258331
- Testing
- CT303
- Where
- 3 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- GC Cell Corporation
Plaque Psoriasis
Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients
M5181 - a novel vitamin D3 analogue - is currently under development for the treatment of plaque psoriasis and is being developed as a topical ointment formulation (M518101) Clinical and non-clinical studies indicate that M5181…
- Trial name
- NCT01989429
- Testing
- M518101
- Where
- 6 sites in Austria, Bulgaria and 4 more
- Volunteers
- 788 people
- Sponsor
- Maruho Europe Limited
Psoriasis
Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients
This study will evaluate the pharmacokinetics and pharmacodynamics of BCT194 in psoriatic patients to better understand the skin penetration of topically applied BCT194.
- Trial name
- NCT01539915
- Testing
- BCT194
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00292396
- Testing
- Anti IL-12 monoclonal antibody/ABT-874
- Where
- 24 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
Real-life Evaluation of the Daivobet® Gel Applicator
This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.
- Trial name
- ASAP PSO (NCT02856542)
- Testing
- calcipotriol/betamethasone dipropionate gel in Applicator
- Where
- France
- Volunteers
- 1,560 people
- Sponsor
- LEO Pharma
Moderate to Severe Plaque Psoriasis
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
This is a first-in-human, phase 1, single-center, randomized, double blinded, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of 608 following subcutaneous injection in healthy subjects.
- Trial name
- NCT04367441
- Testing
- 608
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Plaque Psoriasis
Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis
This is an open label, single center, controlled study with each subject's two treatment plaque areas assigned by the investigator 1:1 to (a) PH-10 with ambient light exposure and (b) PH-10 with 544 nm LED light illumination at…
- Trial name
- NCT00555646
- Testing
- PH-10 (rose bengal disodium 0.001%), Control
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Provectus Pharmaceuticals
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
- Trial name
- NCT06143878
- Testing
- JNJ-77242113, Deucravacitinib
- Where
- 164 sites in United States, Argentina and 11 more
- Volunteers
- 774 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the…
- Trial name
- NCT00384098
- Testing
- CTA018 cream
- Where
- 16 sites in United States
- Volunteers
- 140 people
- Sponsor
- OPKO Health, Inc.
Psoriasis
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00320216
- Testing
- Ustekinumab
- Volunteers
- 320 people
- Sponsor
- Centocor, Inc.
Chronic Plaque Psoriasis
ChangE From Any Systemic psoriasiS therapY to Raptiva
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.
- Trial name
- EASY (NCT00697593)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.
- Trial name
- NCT00098189
- Sponsor
- Novartis
Psoriasis
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) =…
- Trial name
- GUIDE (NCT03818035)
- Testing
- Guselkumab
- Where
- 90 sites in France, Germany
- Volunteers
- 880 people
- Sponsor
- Janssen-Cilag International NV
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
- Trial name
- NCT06220604
- Testing
- JNJ-77242113, Deucravacitinib
- Where
- 128 sites in United States, Australia and 9 more
- Volunteers
- 731 people
- Sponsor
- Janssen Research & Development, LLC
Severe Plaque Psoriasis in Chinese Children
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint…
- Trial name
- NCT07529925
- Testing
- Adalimumab Solution for Injection
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Psoriasis
Clinical Assessment and Psychosocial Impact of Psoriasis
The purpose of this study is to explore the impact of plaque psoriasis on the different dimensions of patient life including psychological disorders, different types of addictions, and their consequences on health-related quality…
- Trial name
- EPIDEPSO (NCT01964443)
- Where
- 48 sites in Austria, Belgium and 10 more
- Volunteers
- 719 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Psoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque…
- Trial name
- HB0017 (NCT06592274)
- Testing
- HB0017
- Where
- 18 sites in China
- Volunteers
- 206 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Active Plaque Psoriasis
Study to Assess VB-201 in Patients With Psoriasis
The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.
- Trial name
- NCT01001468
- Testing
- VB-201
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Psoriasis Vulgaris
Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris
The current most important topical treatments for psoriasis are vitamin D3 analogues and/or corticosteroids. The possibility of another effective treatment for psoriasis could be based on the immunosuppressive efficacy of…
- Trial name
- NCT01743118
- Testing
- SPS4251 Ointment, Daivonex® ointment
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Circassia Limited
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals